Bristol Myers Squibb has secured FDA approval for its cancer drug, Opdivo, to fight microsatellite instability-high colorectal cancer this week after doubts about its ability to fight lung cancer. This form of colorectal cancer affects only 5% of colorectal sufferers, and is difficult to treat with conventional cancer treatments.  This approval signals strong cancer-treating abilities of the BMS drug, which is also being reviewed by investors as a lung cancer treatment. Read the full press release here.